{"protocolSection":{"identificationModule":{"nctId":"NCT02591615","orgStudyIdInfo":{"id":"AFT-09"},"organization":{"fullName":"Alliance Foundation Trials, LLC.","class":"OTHER"},"briefTitle":"Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC","officialTitle":"Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2022-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-01-04","type":"ACTUAL"},"completionDateStruct":{"date":"2020-07-04","type":"ACTUAL"},"studyFirstSubmitDate":"2015-10-20","studyFirstSubmitQcDate":"2015-10-28","studyFirstPostDateStruct":{"date":"2015-10-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-08-18","resultsFirstSubmitQcDate":"2022-11-28","resultsFirstPostDateStruct":{"date":"2022-12-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-11-28","lastUpdatePostDateStruct":{"date":"2022-12-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Alliance Foundation Trials, LLC.","class":"OTHER"},"collaborators":[{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a multicenter randomized phase II to determine if the administration of standard platinum-based chemotherapy before MK-3475 in with Chemotherapy naive stage IV Non-small Cell Lung Cancer (NSCLC) will improve the overall response rate (ORR) compared to MK-3475 administered before chemotherapy. Patients will be given Pembrolizumab as maintenance up to 2 years: Carboplatin and paclitaxel or pemetrexed every 3 weeks x 4 cycles followed by pembrolizumab every 3 weeks for up to 2 years. Pembrolizumab every 3 weeks x 4 cycles followed by carboplatin and paclitaxel or pemetrexed every 3 weeks x 4 cycles followed by pembrolizumab every 3 weeks for up to 2 years.","detailedDescription":"While a genotype-directed strategy has been established as effective in treatment selection for patients with advanced NSCLC, only a minority of patients at this time will have a readily identifiable actionable molecular target. Furthermore, genotype-directed therapy has not been validated for patients with squamous cell carcinoma of the lung. Therefore, the majority of patients with advanced NSCLC will continue to rely on standard platinum-based doublet chemotherapy. Given the plateau in effectiveness of this approach, novel treatment strategies are clearly warranted."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":91,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm A","type":"ACTIVE_COMPARATOR","description":"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\n\nOR\n\nFor Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles","interventionNames":["Drug: Carboplatin","Drug: Paclitaxel","Drug: Pemetrexed"]},{"label":"Arm B","type":"ACTIVE_COMPARATOR","description":"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles\n\nPatients with CR, PR, or SD by irRC will then be treated with:\n\nFor Squamous Carcinoma:\n\nCarboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\n\nOR\n\nFor Non-squamous Carcinoma\n\nCarboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles","interventionNames":["Drug: MK-3475","Drug: Carboplatin","Drug: Paclitaxel","Drug: Pemetrexed"]}],"interventions":[{"type":"DRUG","name":"MK-3475","description":"Dose frequency of Q3W, Day 1 of each cycle","armGroupLabels":["Arm B"],"otherNames":["Pembrolizumab"]},{"type":"DRUG","name":"Carboplatin","description":"Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)","armGroupLabels":["Arm A","Arm B"],"otherNames":["Paraplat","Paraplatin"]},{"type":"DRUG","name":"Paclitaxel","description":"Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)","armGroupLabels":["Arm A","Arm B"],"otherNames":["Taxol"]},{"type":"DRUG","name":"Pemetrexed","description":"Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)","armGroupLabels":["Arm A","Arm B"],"otherNames":["Alimta"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Response Rate (ORR) Per RECIST 1.1","description":"The primary objective of this randomized phase II trial to determine the overall response rate (ORR per RECIST 1.1) in Chemotherapy naive patients with stage IV NSCLC after the administration of standard platinum-based chemotherapy before MK-3475 (arm A) and administration of MK-3475 administered before standard platinum-based chemotherapy (arm B). Overall Response (OR) = CR + PR.","timeFrame":"18 Months"}],"secondaryOutcomes":[{"measure":"Compare Progression-Free Survival (PFS) Per RECIST 1.1","description":"To compare the progression-free survival (PFS) per RECIST 1.1 in previously untreated patients with advanced NSCLC treated with first line carboplatin-based chemotherapy followed by MK-3475 to patients treated with MK-3475 prior to first-line carboplatin-based chemotherapy.","timeFrame":"24 Months"},{"measure":"Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)","description":"To characterize the adverse events related to MK-3475 by frequency, type and grade in patients with Chemotherapy naive advanced NSCLC based on the sequence of administration with first-line chemotherapy. A count of participants experiencing an adverse event is summarized here, the detailed summary is in the adverse events section of this report.","timeFrame":"24 Months"}],"otherOutcomes":[{"measure":"Evaluate the ORR Per irRC","description":"To evaluate the ORR per irRC of MK-3475 administered prior to or after treatment with first-line carboplatin-based chemotherapy in patients with previously untreated NSCLC.","timeFrame":"24 Months"},{"measure":"Evaluate PFS Per irRC","description":"To evaluate the PFS per irRC of previously untreated patients with advanced NSCLC who are treated with MK-3475 administered prior to or after first-line carboplatin-based chemotherapy.","timeFrame":"24 Months"},{"measure":"Evaluate Response Duration of MK-3475","description":"To evaluate the response duration of MK-3475 based on schedule of administration with standard platinum-based chemotherapy in patients with previously untreated advanced NSCLC.","timeFrame":"24 Months"},{"measure":"Evaluate the Overall Survival (OS)","description":"To evaluate the overall survival (OS) of patients with previously untreated advanced NSCLC who received MK-3475 administered prior to or after treatment with first line carboplatin-based chemotherapy.","timeFrame":"24 Months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Be â‰¥ 18 years of age on day of signing informed consent.\n2. Have a life expectancy of at least 3 months.\n3. Have a histologically or cytologically confirmed diagnosis of stage IV NSCLC.\n4. Have a performance status of 0 or 1 on the ECOG.\n5. Have a measurable disease based on RECIST 1.1.\n6. Have provided tissue from an archival tissue sample or newly obtained core or excisional biopsy of tumor lesion.\n7. In patients with non-squamous non-small cell lung cancer, investigators must be able to produce source documentation of the EGFR mutation status or ALK translocation status.\n8. Demonstrate adequate organ function.\n9. Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours.\n10. Female parents of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile.\n11. Male patients must agree to use an adequate method of contraception.\n12. Patients with sensitizing EGFR mutation or ALK rearrangement must have progressed on an appropriate tyrosine kinase inhibitor (TKI)\n\nExclusion Criteria:\n\n1. Has received prior treatment with chemotherapy or biologic therapy for stage IV NSCLC.\n2. Is currently participating in or has participated in a study of an investigational agent or using an investigational device.\n3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy.\n4. Has had a prior mAb within 4 weeks prior to study Day 1 or who has not recovered from adverse events due to agents administered more than 4 weeks earlier.\n5. Has had prior chemotherapy or radiation.\n6. Has a known additional malignancy that is progressing or requires active treatment.\n7. Has known active CNS metastases and/or carcinomatous meningitis.\n8. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.\n9. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.\n10. Has an active infection requiring systemic therapy.\n11. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial.\n12. Has known psychiatric or substance abuse disorders.\n13. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.\n14. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody.\n15. Has a known history of HIV.\n16. Has known active Hepatitis B or Hepatitis C.\n17. Has received a live vaccine within 30 days prior to the planned first dose of study therapy.\n18. Has a known history of active TB.\n19. Hypersensitivity to pembrolizumab or any of it's excipients.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Monica Bertagnolli, MD","affiliation":"Alliance Foundation Trials, LLC.","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Thomas Hensing, MD","affiliation":"Endeavor Health","role":"STUDY_CHAIR"}],"locations":[{"facility":"UCSD Moores Cancer Center","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"The University of Chicago Medical Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"NorthShore University HealthSystem","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"Medical Oncology & Hematology Associates","city":"Des Moines","state":"Iowa","zip":"50309","country":"United States","geoPoint":{"lat":41.60054,"lon":-93.60911}},{"facility":"EMMC Cancer Care","city":"Brewer","state":"Maine","zip":"04412","country":"United States","geoPoint":{"lat":44.79674,"lon":-68.76142}},{"facility":"Metro MN Community Oncology Research Consortium","city":"Minneapolis","state":"Minnesota","zip":"55416","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"NH Oncology (Concord)","city":"Concord","state":"New Hampshire","zip":"03301","country":"United States","geoPoint":{"lat":43.20814,"lon":-71.53757}},{"facility":"Dartmouth Hitchcock Medical Center","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"SUNY Upstate Medical University","city":"Syracuse","state":"New York","zip":"13210","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"The Ohio State University","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"University of Oklahoma Health Sciences Center Stephenson Cancer Center","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}}]},"referencesModule":{"references":[{"pmid":"19097774","type":"BACKGROUND","citation":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026."},{"pmid":"24399786","type":"BACKGROUND","citation":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7."},{"pmid":"23649446","type":"BACKGROUND","citation":"Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e341S-e368S. doi: 10.1378/chest.12-2361."},{"pmid":"11784875","type":"BACKGROUND","citation":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954."},{"pmid":"17167137","type":"BACKGROUND","citation":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884."},{"pmid":"15169807","type":"BACKGROUND","citation":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91. doi: 10.1200/JCO.2004.11.022."},{"pmid":"18506025","type":"BACKGROUND","citation":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27."},{"pmid":"21119545","type":"BACKGROUND","citation":"Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 Jan;6(1):64-70. doi: 10.1097/JTO.0b013e3181f7c6d4."},{"pmid":"19692680","type":"BACKGROUND","citation":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19."},{"pmid":"20573926","type":"BACKGROUND","citation":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530."},{"pmid":"20022809","type":"BACKGROUND","citation":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18."},{"pmid":"21783417","type":"BACKGROUND","citation":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23."},{"pmid":"22285168","type":"BACKGROUND","citation":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Francais de Pneumo-Cancerologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26."},{"type":"BACKGROUND","citation":"Yang, J.C., et al., Overall Survival in Patients with Advanced Non-small Cell Lung Cancer Harboring Common (Del 19/L858R) Epidermal Growth Factor Receptor Mutations: Pooled Analysis of Two Large Open-label Phase III Studies Comparing Afatinib with Chemotherapy. J Clin Oncol, 2014. 32:5s((suppl; abstr 8004))"},{"pmid":"23724913","type":"BACKGROUND","citation":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1."},{"pmid":"24670165","type":"BACKGROUND","citation":"Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107."},{"pmid":"20516428","type":"BACKGROUND","citation":"Disis ML. Immune regulation of cancer. J Clin Oncol. 2010 Oct 10;28(29):4531-8. doi: 10.1200/JCO.2009.27.2146. Epub 2010 Jun 1."},{"pmid":"12091876","type":"BACKGROUND","citation":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug;8(8):793-800. doi: 10.1038/nm730. Epub 2002 Jun 24."},{"pmid":"11910893","type":"BACKGROUND","citation":"Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002 Feb;2(2):116-26. doi: 10.1038/nri727."},{"pmid":"12538684","type":"BACKGROUND","citation":"Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003 Feb 1;170(3):1257-66. doi: 10.4049/jimmunol.170.3.1257."},{"pmid":"20636820","type":"BACKGROUND","citation":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010 Jul;236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x."},{"pmid":"17363529","type":"BACKGROUND","citation":"Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15;13(6):1757-61. doi: 10.1158/1078-0432.CCR-06-2599."},{"pmid":"21876456","type":"BACKGROUND","citation":"Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol. 2011 Oct;6(10):1763-73. doi: 10.1097/JTO.0b013e31822e28fc."},{"pmid":"16421594","type":"BACKGROUND","citation":"Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006 Jan 30;94(2):275-80. doi: 10.1038/sj.bjc.6602934."},{"pmid":"19713832","type":"BACKGROUND","citation":"Zhuang X, Xia X, Wang C, Gao F, Shan N, Zhang L, Zhang L. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):24-8. doi: 10.1097/PAI.0b013e3181b6a741."},{"pmid":"17717638","type":"BACKGROUND","citation":"Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007 Dec;26(3-4):373-400. doi: 10.1007/s10555-007-9072-0."},{"pmid":"9646237","type":"BACKGROUND","citation":"Usubutun A, Ayhan A, Uygur MC, Ozen H, Toklu C, Ruacan S. Prognostic factors in renal cell carcinoma. J Exp Clin Cancer Res. 1998 Mar;17(1):77-81."},{"pmid":"18698040","type":"BACKGROUND","citation":"Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008 Aug 15;14(16):5220-7. doi: 10.1158/1078-0432.CCR-08-0133."},{"pmid":"20385003","type":"BACKGROUND","citation":"Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, Vermorken JB. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010 Apr 12;11:19. doi: 10.1186/1471-2172-11-19."},{"pmid":"17008531","type":"BACKGROUND","citation":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29;313(5795):1960-4. doi: 10.1126/science.1129139."},{"pmid":"18705415","type":"BACKGROUND","citation":"Nobili C, Degrate L, Caprotti R, Franciosi C, Leone BE, Trezzi R, Romano F, Uggeri F, Uggeri F. Prolonged survival of a patient affected by pancreatic adenocarcinoma with massive lymphocyte and dendritic cell infiltration after interleukin-2 immunotherapy. Report of a case. Tumori. 2008 May-Jun;94(3):426-30. doi: 10.1177/030089160809400323."},{"pmid":"20482675","type":"BACKGROUND","citation":"Hodi FS, Dranoff G. The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol. 2010 Apr;37 Suppl 1(0 1):48-53. doi: 10.1111/j.1600-0560.2010.01506.x."},{"pmid":"19717085","type":"BACKGROUND","citation":"Kloor M. Lymphocyte infiltration and prognosis in colorectal cancer. Lancet Oncol. 2009 Sep;10(9):840-1. doi: 10.1016/S1470-2045(09)70245-1. No abstract available."},{"pmid":"18941457","type":"BACKGROUND","citation":"Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008 Nov 18;99(10):1704-11. doi: 10.1038/sj.bjc.6604738. Epub 2008 Oct 21."},{"pmid":"18791714","type":"BACKGROUND","citation":"Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009 Mar;58(3):449-59. doi: 10.1007/s00262-008-0583-5. Epub 2008 Sep 13."},{"pmid":"10704469","type":"BACKGROUND","citation":"Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med. 2000 Mar 6;191(5):891-8. doi: 10.1084/jem.191.5.891."},{"pmid":"20924634","type":"BACKGROUND","citation":"Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol. 2010 Dec;15(6):544-51. doi: 10.1007/s10147-010-0130-1. Epub 2010 Oct 6."},{"pmid":"20735382","type":"BACKGROUND","citation":"Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, Santarlasci V, Serni S, Cosmi L, Maggi L, Angeli R, Mazzinghi B, Romagnani P, Maggi E, Carini M, Romagnani S, Annunziato F. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011 May;107(9):1500-6. doi: 10.1111/j.1464-410X.2010.09555.x. Epub 2010 Aug 24."},{"pmid":"20373055","type":"BACKGROUND","citation":"Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011 Sep;28(3):682-8. doi: 10.1007/s12032-010-9515-2. Epub 2010 Apr 6."},{"pmid":"24419410","type":"BACKGROUND","citation":"Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol. 2014 Feb;9(2):144-53. doi: 10.1097/JTO.0000000000000074."},{"pmid":"23389362","type":"BACKGROUND","citation":"Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012 Nov;98(6):751-5. doi: 10.1177/030089161209800612."},{"pmid":"17920123","type":"BACKGROUND","citation":"Zhang P, Su DM, Liang M, Fu J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24."},{"pmid":"22658128","type":"BACKGROUND","citation":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2."},{"type":"BACKGROUND","citation":"Spigel, D., et al., Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastic non-small cell lung cancer. J Clin Oncol, 2013. 31(Suppl; abstr 8008)."},{"type":"BACKGROUND","citation":"Garon, E., et al., Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer: Preliminary safety and clinical activity. . Clin Cancer Res, 2014. 20: p. A20."},{"type":"BACKGROUND","citation":"Garon, E., et al., Safety and Clinical Activity of MK-3475 in Previously Treated Patients with Non-small Cell Lung CAncer. J Clin Oncol, 2014. 32:5S((suppl;abstr 8020))."},{"type":"BACKGROUND","citation":"Rizvi, N., et al., Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients with Advanced Non-small Cell Lung Cancer. J Clin Oncol, 2014. 32:5s((suppl; abstr 8007))."},{"type":"BACKGROUND","citation":"Gettinger, S.N., et al., First-line Nivolumab Monotherapy in Advanced NSCLC: Safety, Efficacy, and Correlation with PD-L1 Status. . J Clin Oncol, 2014. 325s((suppl; abstr 8024))."},{"type":"BACKGROUND","citation":"Brahmer, J., et al., Survival and long-term follow up of phase I trial of nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in patients with previously treated advanced non-small cell lung cancer. J Clin Oncol, 2013. 31(suppl; abstr 8030)."},{"pmid":"19997099","type":"BACKGROUND","citation":"Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010 Jan 5;102(1):115-23. doi: 10.1038/sj.bjc.6605465. Epub 2009 Dec 8."},{"pmid":"20302610","type":"BACKGROUND","citation":"John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, Pandha H. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol. 2010 Mar 19;11:14. doi: 10.1186/1471-2172-11-14."},{"pmid":"18771959","type":"BACKGROUND","citation":"Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, Zhang Y, Cai Y, Chu Y, Xiong S. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol. 2008 Nov;129(2):219-29. doi: 10.1016/j.clim.2008.07.013. Epub 2008 Sep 3."},{"type":"BACKGROUND","citation":"Antonia, S.J., et al., Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy in advanced non-small cell lung cancer. J Clin Oncol, 2014. 32:5s((suppl; abstr 8113))."},{"pmid":"23626745","type":"BACKGROUND","citation":"Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW, Lake RA. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 2013 Apr 23;8(4):e61895. doi: 10.1371/journal.pone.0061895. Print 2013."},{"pmid":"22547592","type":"BACKGROUND","citation":"Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun 10;30(17):2046-54. doi: 10.1200/JCO.2011.38.4032. Epub 2012 Apr 30."},{"pmid":"25096781","type":"BACKGROUND","citation":"Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol. 2014 Dec;15(4):658-69. doi: 10.1007/s11864-014-0305-5."},{"pmid":"19934295","type":"BACKGROUND","citation":"Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24."},{"pmid":"4075313","type":"BACKGROUND","citation":"Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985 Dec;69(12):1375-81."},{"type":"BACKGROUND","citation":"Fleiss, J., L. B, and M. Paik, Statistical Methods for Rates and Proportions, J.W. Sons, Editor. 2003: New York."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Arm A Squamous Carcinoma (Platinum Doublet, Then MK-3475, Then Maintenance MK-3475)","description":"For Squamous Carcinoma\\>\n\n\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\>\n\n\\>\n\n\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\>\n\n\\>\n\n\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\>\n\n\\>\n\n\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"FG001","title":"Arm A Non-squamous Carcinoma (Platinum Doublet, Then MK-3475, Then Maintenance MK-3475)","description":"For Non-squamous Carcinoma\\>\n\n\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"FG002","title":"Arm B Squamous Carcinoma (Pembro, Then MK-3475, Then Platinum Doublet, Then Maintenance MK-3475)","description":"For Squamous Carcinoma:\\> \\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\>\n\n\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"FG003","title":"Arm B Non-squamous Carcinoma (Pembro, Then MK-3475, Then Platinum Doublet, Then Maintenance MK-3475)","description":"For Non-squamous Carcinoma\\> \\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> MK-3475: Dose frequency of Q3W, Day 1 of each cycle\\>\n\n\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"}],"periods":[{"title":"Arm B Pembro Lead in Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"34"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"37"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"34"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"37"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"Platinum Doublet Arm A, MK-3475 Arm B","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"34"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"37"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"17"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"12"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Deemed ineligible","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrew to hospice","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Non compliance","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"MK-3475 Arm A, Platinum Doublet Arm B","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"18"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Alternative Therapy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"Maintenance MK-3475","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"18"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"11"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"8"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Physician discretion","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrew to hospice","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"In active treatment","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm A Squamous Carcinoma","description":"For Squamous Carcinoma\\>\n\n\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"BG001","title":"Arm A Non-squamous Carcinoma","description":"For Non-squamous Carcinoma\\> \\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\>\n\n\\>\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"BG002","title":"Arm B Squamous Carcinoma","description":"For Squamous Carcinoma:\\>\n\n\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"BG003","title":"Arm B Non-squamous Carcinoma","description":"For Non-squamous Carcinoma\\> \\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\> MK-3475: Dose frequency of Q3W, Day 1 of each cycle\\>\n\n\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"91"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65","lowerLimit":"50","upperLimit":"77"},{"groupId":"BG001","value":"69","lowerLimit":"40","upperLimit":"83"},{"groupId":"BG002","value":"67","lowerLimit":"48","upperLimit":"71"},{"groupId":"BG003","value":"68","lowerLimit":"48","upperLimit":"80"},{"groupId":"BG004","value":"68","lowerLimit":"40","upperLimit":"83"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"43"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"48"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"91"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"8"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"79"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate (ORR) Per RECIST 1.1","description":"The primary objective of this randomized phase II trial to determine the overall response rate (ORR per RECIST 1.1) in Chemotherapy naive patients with stage IV NSCLC after the administration of standard platinum-based chemotherapy before MK-3475 (arm A) and administration of MK-3475 administered before standard platinum-based chemotherapy (arm B). Overall Response (OR) = CR + PR.","populationDescription":"All patients that started treatment are included in analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"proportion of participants","timeFrame":"18 Months","groups":[{"id":"OG000","title":"Arm A (Both Squamous and Non-Squamous)","description":"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles OR For Non-squamous Carcinoma\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy) Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy) Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"OG001","title":"Arm B (Both Squamous and Non-Squamous)","description":"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles\\> \\>\\>\n\n\\>\n\n\\>\\> Patients with CR, PR, or SD by irRC will then be treated with:\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> For Squamous Carcinoma:\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\>\\> Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> OR\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> For Non-squamous Carcinoma\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\>\\> Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> MK-3475: Dose frequency of Q3W, Day 1 of each cycle\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.395","lowerLimit":"0.249","upperLimit":"0.541"},{"groupId":"OG001","value":"0.404","lowerLimit":"0.264","upperLimit":"0.545"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2176","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Compare Progression-Free Survival (PFS) Per RECIST 1.1","description":"To compare the progression-free survival (PFS) per RECIST 1.1 in previously untreated patients with advanced NSCLC treated with first line carboplatin-based chemotherapy followed by MK-3475 to patients treated with MK-3475 prior to first-line carboplatin-based chemotherapy.","populationDescription":"All patients that were treated were included in analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"24 Months","groups":[{"id":"OG000","title":"Arm A (Both Squamous and Non-Squamous)","description":"For Squamous Carcinoma\\>\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\\> Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\\>\n\n\\>\\> OR\\>\\>\n\n\\>\\> For Non-squamous Carcinoma\\>\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\\> Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\\>\n\n\\>\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\\>\n\n\\>\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\\>\n\n\\>\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"OG001","title":"Arm B (Both Squamous and Non-Squamous)","description":"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles\\>\\> \\>\\> Patients with CR, PR, or SD by irRC will then be treated with:\\>\\>\n\n\\>\\> For Squamous Carcinoma:\\>\\>\n\n\\>\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\\> Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\\>\n\n\\>\\> OR\\>\\>\n\n\\>\\> For Non-squamous Carcinoma\\>\\>\n\n\\>\\> Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles\\>\\> Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles\\>\\>\n\n\\>\\> MK-3475: Dose frequency of Q3W, Day 1 of each cycle\\>\\>\n\n\\>\\> Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\\>\n\n\\>\\> Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)\\>\\>\n\n\\>\\> Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"4.4","upperLimit":"10.6"},{"groupId":"OG001","value":"4.0","lowerLimit":"2.1","upperLimit":"10.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.84","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.67","ciUpperLimit":"1.64"}]},{"type":"SECONDARY","title":"Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)","description":"To characterize the adverse events related to MK-3475 by frequency, type and grade in patients with Chemotherapy naive advanced NSCLC based on the sequence of administration with first-line chemotherapy. A count of participants experiencing an adverse event is summarized here, the detailed summary is in the adverse events section of this report.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"24 Months","groups":[{"id":"OG000","title":"Arm A Squamous Carcinoma","description":"Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"OG001","title":"Arm A Non-squamous Carcinoma","description":"Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"OG002","title":"Arm B Squamous Carcinoma","description":"Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"},{"id":"OG003","title":"Arm B Non-squamous Carcinoma","description":"Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"37"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Evaluate the ORR Per irRC","description":"To evaluate the ORR per irRC of MK-3475 administered prior to or after treatment with first-line carboplatin-based chemotherapy in patients with previously untreated NSCLC.","reportingStatus":"NOT_POSTED","timeFrame":"24 Months","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Evaluate PFS Per irRC","description":"To evaluate the PFS per irRC of previously untreated patients with advanced NSCLC who are treated with MK-3475 administered prior to or after first-line carboplatin-based chemotherapy.","reportingStatus":"NOT_POSTED","timeFrame":"24 Months","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Evaluate Response Duration of MK-3475","description":"To evaluate the response duration of MK-3475 based on schedule of administration with standard platinum-based chemotherapy in patients with previously untreated advanced NSCLC.","reportingStatus":"NOT_POSTED","timeFrame":"24 Months","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Evaluate the Overall Survival (OS)","description":"To evaluate the overall survival (OS) of patients with previously untreated advanced NSCLC who received MK-3475 administered prior to or after treatment with first line carboplatin-based chemotherapy.","reportingStatus":"NOT_POSTED","timeFrame":"24 Months","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"24 months","description":"The descriptions and grading scales found in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4 will be utilized for AE reporting.","eventGroups":[{"id":"EG000","title":"MK-3475","description":"MK-3475 200 mg Q3W","deathsNumAffected":35,"deathsNumAtRisk":67,"seriousNumAffected":17,"seriousNumAtRisk":67,"otherNumAffected":66,"otherNumAtRisk":67},{"id":"EG001","title":"Carboplatin + Pemetrexed","description":"For Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy) Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy) Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)","deathsNumAffected":10,"deathsNumAtRisk":47,"seriousNumAffected":6,"seriousNumAtRisk":47,"otherNumAffected":46,"otherNumAtRisk":47},{"id":"EG002","title":"\"Carboplatin + Paclitaxel\"","description":"Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles MK-3475: Dose frequency of Q3W, Day 1 of each cycle Carboplatin: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy) Paclitaxel: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy) Pemetrexed: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)","deathsNumAffected":5,"deathsNumAtRisk":13,"seriousNumAffected":4,"seriousNumAtRisk":13,"otherNumAffected":12,"otherNumAtRisk":13}],"seriousEvents":[{"term":"Blood and lymph sys disorders - Oth Spec","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Heart failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Musculoskeletal, conn tissue - Oth spec","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Nervous system disorders - Oth spec","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Adult respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Resp, thoracic, mediastinal - Oth spec","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":29,"numAtRisk":67},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":47},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":13}]},{"term":"Blood and lymph sys disorders - Oth Spec","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Lymph node pain","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Cardiac disorders - Other, specify","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Chest pain - cardiac","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Heart failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hearing impaired","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Blurred vision","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Eye disorders - Other, specify","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Eyelid function disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Floaters","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Watering eyes","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":67},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":11,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Bloating","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":29,"numAtRisk":67},{"groupId":"EG001","numEvents":21,"numAffected":20,"numAtRisk":47},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":13}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":12,"numAtRisk":67},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":47},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":13}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Gastroesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Gastrointestinal disorders - Oth spec","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Mucositis oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":27,"numAtRisk":67},{"groupId":"EG001","numEvents":34,"numAffected":26,"numAtRisk":47},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":13}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Rectal hemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Stomach pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":67},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":13}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Edema face","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Edema limbs","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":14,"numAtRisk":67},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":47},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":13}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":74,"numAffected":45,"numAtRisk":67},{"groupId":"EG001","numEvents":39,"numAffected":29,"numAtRisk":47},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":13}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Flu like symptoms","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Gen disord and admin site conds-Oth spec","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Localized edema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":13}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":13,"numAtRisk":67},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":47},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":13}]},{"term":"Hepatobiliary disorders - Other, specify","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Allergic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Immune system disorders - Other, specify","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Gum infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Mucosal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Upper respiratory infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Bruising","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Inj, pois and proced complic - Oth spec","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Activated partial throm time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":67},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":4,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Cardiac troponin T increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"INR increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Investigations - Other, specify","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":7,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":7,"numAffected":2,"numAtRisk":13}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Weight gain","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":13}]},{"term":"Weight loss","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":8,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":30,"numAtRisk":67},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":47},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":13}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hypercalcemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":67},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":47},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":13}]},{"term":"Hyperkalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Hypernatremia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Hyperuricemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Hypocalcemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Hypoglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":67},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hyponatremia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":13}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":12,"numAtRisk":67},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":67},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":47},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":13}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Buttock pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Chest wall pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Generalized muscle weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Muscle weakness lower limb","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Muscle weakness upper limb","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Musculoskeletal, conn tissue - Oth spec","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":12,"numAtRisk":67},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Cognitive disturbance","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Concentration impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":67},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":67},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":47},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":13}]},{"term":"Facial muscle weakness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":13,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Paresthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":13,"numAtRisk":67},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":47},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":13}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":11,"numAtRisk":67},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":13}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":67},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":21,"numAtRisk":67},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":47},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":13}]},{"term":"Libido decreased","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Renal and urinary disorders - Oth spec","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Urinary frequency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Urinary tract pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Urinary urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Penile pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Allergic rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":31,"numAtRisk":67},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":27,"numAtRisk":67},{"groupId":"EG001","numEvents":17,"numAffected":14,"numAtRisk":47},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":13}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hoarseness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Laryngeal hemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Pharyngeal hemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Postnasal drip","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Resp, thoracic, mediastinal - Oth spec","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Sinus disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Sinus pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Sore throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":13}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":67},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":13}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":67},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":47},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":13}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Nail discoloration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Nail ridging","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":67},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Rash acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":67},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":47},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":13}]},{"term":"Scalp pain","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Skin and subcut tissue disord - Oth spec","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Skin ulceration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":67},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Surgical and medical proced - Oth spec","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hot flashes","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":9,"numAtRisk":67},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":47},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":13}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":67},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":47},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":13}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Thomas Hensing","organization":"NorthShore Medical Group","email":"thensing@northshore.org","phone":"847.570.2112"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2017-09-14","uploadDate":"2022-05-09T09:33","filename":"Prot_SAP_000.pdf","size":15430191}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}